Conexxence (denosoumab)
pCPA File Number:
23491
Negotiation Status:
Active Negotiation
Indication(s):
• treatment of postmenopausal women with osteoporosis at high risk for fracture;
• treatment to increase bone mass in men with osteoporosis at high risk for fracture;
• treatment to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy, who are at high risk for fracture;
• treatment to increase bone mass in women receiving adjuvant aromatase inhibitor therapy for nonmetastatic breast cancer; and
• treatment to increase bone mass for the treatment and prevention of glucocorticoid- induced osteoporosis in women and men at high risk for fracture
• treatment to increase bone mass in men with osteoporosis at high risk for fracture;
• treatment to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy, who are at high risk for fracture;
• treatment to increase bone mass in women receiving adjuvant aromatase inhibitor therapy for nonmetastatic breast cancer; and
• treatment to increase bone mass for the treatment and prevention of glucocorticoid- induced osteoporosis in women and men at high risk for fracture
Sponsor/Manufacturer:
Fresenius Kabi Canada Ltd.
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable